Taking low doses of aspirin can reduce the risk of many kinds of cancer.
A report by scientists reveals that the evidence is strong enough to suggest people over 40 should take aspirin daily as protection.
In a study of eight trials involving 25,570 patients, researchers found that cancer deaths among those who took aspirin in doses as low as 75 milligrams a day were 21 percent lower during the studies and 34 percent lower after five years.
Aspirin protected people against gastrointestinal cancers the most, the study found, with rates of death from these cancers around 54 percent lower after five years among those who took aspirin compared to those who did not.
Researchers at Oxford University noted that while taking aspirin carries a small risk of stomach bleeding, that risk was beginning to be “drowned out” by its benefits in reducing the risk of cancer and the risk of heart attacks.
Previous studies have found taking aspirin can cut the risk of developing colon or bowel cancer and suggested it does so by blocking the enzyme cyclooxygenase2 which promotes inflammation and cell division and is found in high levels in tumors.
In the latest study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.
Posted by the American Association for Long-Term Care Insurance which tracks relevant health news stories.
LEARN MORE ABOUT LONG-TERM CARE INSURANCE PROTECTION. Get a free, no obligation quote for Long-Term Care Insurance from the American Association for Long-Term Care Insurance. Click here now!
INSURANCE AGENTS. SELL MORE LONG-TERM CARE INSURANCE PROTECTION. Visit the Association's Online LTC Learning, Marketing & Sales Center. Click here now!
HAVE YOU HEARD ABOUT CRITICAL ILLNESS INSURANCE? Learn more from the American Association for Critical Illness Insurance. Click here now!
MEDICARE SUPPLEMENT INSURANCE COSTS
Click here to learn more!